Disitamab vedotin in combination with immune checkpoint inhibitors for locally and locally advanced bladder urothelial carcinoma: a two-center’s real-world study

Objective: Our study aims to assess the effectiveness and safety profile of Disitamab Vedotin (DV, RC48-ADC), an innovative humanized anti-HER2 antibody conjugated with tubulin-disrupting antimitotic drug monomethyl auristatin E (MMAE) via a cleavable peptide linker. This treatment combined immune c...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Yongbao, Zhang, Ruochen, Yu, Chenbo, Hong, Zhiwei, Lin, Le, Li, Tao, Chen, Jianhui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10461006/
https://www.ncbi.nlm.nih.gov/pubmed/37645442
http://dx.doi.org/10.3389/fphar.2023.1230395

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10461006/
https://www.ncbi.nlm.nih.gov/pubmed/37645442
http://dx.doi.org/10.3389/fphar.2023.1230395

Ejemplares similares